What are weight loss peptides?

Compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction.

How many weight loss peptides are researched on HEXAGEN?

HEXAGEN currently covers 17 compounds in the Weight Loss category, including AOD-9604, CJC-1295, Ipamorelin, and 14 more. Each compound has a detailed profile covering mechanism, research highlights, molecular data, and scientific references.

What mechanisms do weight loss peptides target?

Weight loss peptides target β3-adrenergic lipolysis, GHRH receptor agonism for growth hormone release, ghrelin receptor agonism, GLP-1 and GIP receptor agonism for appetite suppression, and NNMT enzyme inhibition for fat oxidation. Each mechanism addresses fat metabolism through distinct endocrine pathways.

Are weight loss peptides FDA-approved?

Tesamorelin (Egrifta®), Semaglutide (Wegovy®/Ozempic®), Tirzepatide (Mounjaro®/Zepbound®), and Somatropin are FDA-approved for specific indications. Other compounds like AOD-9604, CJC-1295, and Ipamorelin are research chemicals without FDA approval.

What is the research status of weight loss peptides?

Tesamorelin, Semaglutide, and Tirzepatide have Phase III clinical data and FDA approval. Other compounds range from Phase I/II trials (CJC-1295) to preclinical research (AOD-9604, HGH Fragment 176-191).

Where can I learn more about individual weight loss compounds?

Each compound in the Weight Loss category has a dedicated research profile. Visit the compound pages linked on this pillar page for detailed mechanism of action, molecular structure, research highlights, FAQs, and scientific references.